Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (12149)	3/16/2015 10:03:06 AM
From: Goose94	Read Replies (1) \| Respond to of 202710

PHM-V new 52 week high, $1.30

To: Goose94 who wrote (12149)	3/31/2015 10:00:54 AM
From: Goose94	Read Replies (1) \| Respond to of 202710

PHM-V new 52 week high, $1.56

To: Goose94 who wrote (12149)	4/13/2015 8:10:21 AM
From: Goose94	Read Replies (1) \| Respond to of 202710

Patient Home Monitoring (PHM-V) April 13, '15 a profitable company with annualized revenues of $60 million focused on rolling-up annuity-based healthcare service companies in the U.S. and Canada, is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Mackie Research Capital Corporation (the "Underwriters"), whereby the Underwriters will purchase, on a bought-deal basis, 24,000,000 units (the "Units") of PHM at a price of $1.50 per Unit for gross proceeds to PHM of $36,000,000 (the "Offering"). Each Unit will consist of one (1) common share (a "Common Share") in the capital of PHM and one-half (1/2) of one common share purchase warrant (each whole common share purchase warrant a "Warrant") of PHM. Each Warrant entitles the holder thereof to acquire one Common Share for an exercise price of $1.80 per Common Share for a period of 36 months following closing of the Offering (the "Closing"). The expiry date of the Warrants may be accelerated by PHM at any time following the six-month anniversary of the Closing and prior to the expiry date of the Warrants when the volume-weighted average trading price of the Common Shares is greater than $2.20 for any 20 consecutive trading days, at which time PHM may accelerate the expiry date of the Warrants by issuing a press release announcing the reduced warrant term whereupon the Warrants will expire on the 20th calendar day after the date of such press release. PHM has granted the Underwriters an option (the "Agent's Option") to increase the size of the Offering by up to an additional 15% of the total number of Units to be issued under the Offering, at any time on or before 48 hours prior to the Closing. The Offering is scheduled to close on or about the week of May 4th, 2015 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities to be issued under the Offering will have a hold period of four months and one day from the Closing. The net proceeds from the Offering will be used by PHM for acquisition purposes and general working capital. In consideration for their services, the Underwriters will receive a cash commission of 5.0% of the gross proceeds of the Offering, and shall receive such number of compensation options exercisable into Common Shares, as is equal to 4.0% of the Units issued pursuant to the Offering. About PHM PHM is an acquisition-oriented, fast-growing and profitable company servicing patients with heart disease and other chronic health conditions. PHM is focused on acquiring companies in a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity. Because of the new and highly fragmented nature of the market, PHM is actively identifying and evaluating profitable, annuity-based companies to acquire at favorable prices for their patient databases and technical expertise. PHM's post-acquisition organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient. The expected result is growing EPS with each acquisition and growing revenue and profits from the cross selling efforts. Patient Home Monitoring Corp. Dennis Wilson Corporate Affairs investorinfo@myphm.com www.phmhometesting.com